Jocelyn Aspa

Jocelyn obtained her diploma in journalism from Langara College in April 2016, just prior to joining INN as a staff writer for the resource sector. Since then, Jocelyn has shifted to covering the life science space and has become managing editor for INN's technology, cannabis and life science divisions. Jocelyn is passionate about niche topics within the life science sector and enjoys shedding light on companies focused on unmet clinical needs.

Prior to joining INN, Jocelyn interned at the Georgia Straight and blogged about the Vancouver Canucks. Before following her career in journalism, Jocelyn spent several years working in law firms. She thrives off the knowledge her background brings to her reporting.

jaspa@investingnews.com

Articles

Applied Therapeutics Starts Phase 1/2 Study of AT-007

Applied Therapeutics (NASAQ:APLT) has announced it has started its Phase 1/2 study of AT-007 in galactosemia. As quoted in the...

June 24th, 2019

BrainsWay Announces Shipment of 100th Deep Transcranial Magnetic Stimulation Helmet

BrainsWay (NASDAQ:BWAY, TASE:BWAY) has announced that it has shipped its 100th Deep Transcranial Magnetic Stimulation (Deep TMS) system to treat...

June 24th, 2019

Krystal Biotech Announces Positive Results from Phase 2 Clinical Trial

Krystal Biotech (:NASDAQ:KRYS) has announced positive results from its Phase 2 clinical trial of KB103 (GEM-2). As quoted in the...

June 24th, 2019

5 Top Weekly NASDAQ Biotech and Pharma Stocks: Melinta Leads

Which companies were last week's top gainers? We break down the five top NASDAQ biotech and pharma stocks of the...

June 23rd, 2019

Ocular Therapeutix™ Announces FDA Approval of Supplemental New Drug Application (sNDA) for DEXTENZA®

Ocular Therapeutics (NASDAQ:OCUL) has announced that the US Food and Drug Administration (FDA) has approved a supplemental new drug application...

June 21st, 2019

Catabasis Pharmaceuticals Presents Preclinical Data of Edasalonexent

Catabasis Pharmaceuticals (NASDAQ:CATB) has announced preclinical data for its edasalonexent in Phase 2 development to treat Duchenne musclar dystrophy (DMD)....

June 21st, 2019

ContraVir Pharmaceuticals Receives FDA Response to CRV431

ContraVir Pharmaceuticals (NASDAQ:CTRV) has announced that the US Food and Drug Administration (FDA) has responded positively to the company’s pre-investigational...

June 21st, 2019